P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

Marco Valgimigli(University of Bern), Roxana Mehran(Icahn School of Medicine at Mount Sinai), C. Michael Gibson(Brigham and Women's Hospital), Yangsoo Jang(Yonsei University), Sung‐Jin Hong(Inje University Sanggye Paik Hospital), Yunpeng Zhu(Shanghai Jiao Tong University), Felice Gragnano(Ospedale Sant'Anna), Peter Jüni(St. Michael's Hospital), Dominick J. Angiolillo(Jacksonville University), Young Bin Song(Samsung Medical Center), Dik Heg, Stephan Windecker, George Dangas, Shamir R. Mehta(Population Health Research Institute), Pascal Vranckx(Jessa Hospital), Kenji Andò(Kokura Memorial Hospital), Patrick W. Serruys(Ollscoil na Gaillimhe – University of Galway), Hirotoshi Watanabe(Kyoto University), Hyeon‐Cheol Gwon(Samsung Medical Center), Usman Baber(Icahn School of Medicine at Mount Sinai), Joo‐Yong Hahn(Samsung Medical Center), Anna Franzone(University Hospital of Bern), Mattia Branca, Takeshi Kimura(Kyoto University), Qiang Zhao(Ruijin Hospital), Eugène McFadden(Skadden Arps Slate Meagher & Flom), Byeong‐Keuk Kim(Ewha Womans University)
BMJ
June 16, 2021
Cited by 254


Related Papers